Physician profile
Bryce C Fitzpatrick
NPI 1245755404
$2,753.75
in general payments reported to CMS, 2019-2025
21 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $311 · 2023: $1,075 · 2024: $705 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $482.84 | 2021-2025 | Proclaim, Prodigy |
| Medtronic, INC. | $477.83 | 2023-2025 | Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $370.37 | 2022-2024 | Superion Indirect Decompression System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $281.49 | 2021-2024 | Relistor |
| Protega Pharmaceutials INC | $188.67 | 2024-2025 | Roxybond |
| Nalu Medical, INC. | $182.02 | 2021-2024 | Nalu Neurostimulation System |
| Relievant Medsystems, INC. | $167.73 | 2023 | Intracept |
| Stryker Corporation | $107.67 | 2024 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $96.50 | 2024-2025 | Xtampza |
| Abbvie INC. | $91.10 | 2021-2024 | |
| Spr Therapeutics, INC | $80.74 | 2024-2025 | Sprint Pns System |
| Averitas Pharma INC. | $48.53 | 2023-2024 | Qutenza |
| Valinor Pharma, LLC | $36.46 | 2024 | Movantik |
| Painteq LLC | $26.90 | 2022 | |
| Almatica Pharma LLC | $22.38 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $20.01 | 2023 | Biotronik |
| Biodelivery Sciences International, INC. | $16.78 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.94 | 2021 | |
| Tersera Therapeutics LLC | $11.86 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.